CN102641258B - Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof - Google Patents
Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof Download PDFInfo
- Publication number
- CN102641258B CN102641258B CN 201210122530 CN201210122530A CN102641258B CN 102641258 B CN102641258 B CN 102641258B CN 201210122530 CN201210122530 CN 201210122530 CN 201210122530 A CN201210122530 A CN 201210122530A CN 102641258 B CN102641258 B CN 102641258B
- Authority
- CN
- China
- Prior art keywords
- water
- molecular weight
- weight
- soluble high
- micropowder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a spongy dextromethorphan hydrobromide film agent with micro-pore and a preparation method of the film agent; the spongy dextromethorphan hydrobromide film agent with micro-pore comprises the following components: a dextromethorphan hydrobromide, a water-soluble polymer material, and a water-insoluble micro-powder dispersed in the water-soluble polymer material; the water-soluble polymer material is any two of HPMC (hydroxy propyl methyl cellulose), PVA (polyvinyl alcohol), HPC (hydroxy propyl cellulose), CMC-NA (sodium carboxyl methyl cellulose), PVP (polyvinyl pyrrolidone), sodium alginate or PEO (polyethylene oxide), and wherein one is a lower molecular weight water-soluble polymer material with molecular weight of 10, 000-200, 000 Dalton, the other one is a higher molecular weight water-soluble polymer material with molecular weight of 200, 000-10, 000, 000 Dalton. According to the invention, effects are very significant; films are dissolved fast through the lower molecular weight water-soluble polymer material, physical strength and toughness of films are ensured through the higher molecular weight water-soluble polymer material so as to realize the purpose of quick release and ensure strength of films.
Description
Technical field
The present invention relates to a kind of Suppress.
Background technology
A kind of defensive reflex activity that cough produces when being the respiratory system irriate.Slight cough is conducive to expectoration, generally need not use cough medicine, but serious cough, particularly violent dry cough without expectorant can affect rest and sleep, or causes other complication, needs the use cough medicine.
Dextromethorphan (Dextromethorphan) is morphine class nervus centralis cough medicine, uses clinically its hydrobromate, is an important force of being a dark horse in market, oral antitussive in recent years., registered in China in 1988 in exploitation listing in 1954 by Roche Holding Ag.The multiple dosage form products such as existing tablet, capsule, granule, dry suspension, syrup are got permission production, import or are entered the new drug clinical stage so far.
A little less than child and the old people's passive protective physical fitness, easily catch a cold, the disease such as cough.The taste of dextromethorphan is bitter and numb, and existing kind is taken inconvenience concerning the old man of child and dysphagia.Easy to use, evident in efficacy, rapid-action, the dextromethorphan formulation products that side effect is little of being badly in need of that development and production is fit to that they use.
Membrane does not need water delivery service, especially is fit to the old man of child and dysphagia; Be placed on the tongue instantly, and be difficult for after sticking spuing.Compare with liquid preparations such as drop, syrups, dosage is accurate; Compare with the lyophilizing sheet with oral cavity quick disintegrating slice, production technology is simple, and cost is lower.In recent years, this dosage form comes into one's own gradually.
The medicine film preparation is as far back as i.e. existing many researchs of nineteen seventies, such as tranquilizer film (Chinese Journal of Pharmaceuticals, 1976,12 (19)), diphenoxylate medicine film (Chinese Journal of Pharmaceuticals, 1976,12 (22)), external applied contraceptive film (Chinese Journal of Pharmaceuticals, 1977,4-5 (45)), nitroglycerin medicine film (Chinese Journal of Pharmaceuticals, 1977,12 (5)), rhodexin film (Chinese Journal of Pharmaceuticals, 1980,4 (18)), clonidine sustained release film formulation (Chinese Journal of Pharmaceuticals, 1981,3 (141)) etc.Chinese Pharmacopoeia is also recorded (Pharmacopoeia of People's Republic of China 1995 editions, 2000 editions, 2005 editions, 2010 editions) to membrane as official preparation.This dosage form for various reasons at home, fast development is not arranged so far, also get permission to produce at home there are no new medicine film, may with lack modern production machine, it is relevant to lack packing attractive in appearance easy to use, for this reason, the inventor has applied for the patent of new packaged form of packaging machine, the membrane of production machine, the membrane of membrane, to promote membrane development at home.
By contrast, abroad membrane in development rapidly and vigorously, as the membrane of nonprescription drugs, the U.S. FDA approved 9 products and going on the market, such as the breath freshening membrane, antianaphylactic diphenhydramine membrane etc.
Membrane is also easily manufactured because of it as prescription drugs, adjuvant is few, easy to carry, do not need the water clothes, rapid-action, more the economic dispatch many merits is replacing oral cavity disintegration tablet, the lyophilizing sheet, the oral formulations such as dispersible tablet, and present many patents, as paste mucoadhesive films (US pat on oral mucosa, 6750,921), can be bonded at and slowly lose again molten membrane (USpat in the oral cavity, 5800,832), double-deck membrane (US pat is also arranged, 5700,478), non-oral cavity adhesion is arranged also, the membrane (WO 2008040534 (A2)) of meeting disintegrate in the oral cavity.Numerous membrane are used for pain relieving, sleep disorder etc., be particularly suitable for engulfing patient, child, the easy patient that vomiting occurs of difficulty, U.S. FDA has been ratified the famotidine film in 2005, ratified again the production of ondansetron film in 2010, sign prescriptions film will come into the market with speed faster.
The water solublity of dextromethorphan hydrobromide is relatively poor, need to be dispersed in the macromolecular material; And its bitter in the mouth needs to add correctives and odor mask; Add the adding of insoluble micropowder in the pore creating material, the large percentage of the water insoluble active ingredient in the prescription.The inventor finds, when the large percentage of water insoluble active ingredient in the film prescription, film is more crisp, and is frangible.Be unfavorable for producing, transport, preserve and use.Common way is the plasticizer that adds q.s, but when increasing the plasticizer ratio, the ratio of macromolecular material reduces relatively, is unfavorable for the molding of film.If will in the macromolecule ratio hour guarantee film strength, will use higher molecular weight, material that viscosity is larger, like this, the dissolving of film will be slowed down, and does not reach the effect of rapid onset.
And when adopting the inventor when the technology of the patent disclosure of first to file prepares the dextromethorphan hydrobromide membrane, test finds, also exist film more crisp, cut with packaging process in frangible defective, need to be improved.
Summary of the invention
One of purpose of the present invention provides a kind of spongiform dextromethorphan hydrobromide membrane with micropore and preparation method thereof, and the defective that exists to overcome prior art satisfies clinical needs.
Spongiform dextromethorphan hydrobromide membrane with micropore of the present invention, its component comprise dextromethorphan hydrobromide, water-soluble high-molecular material and are dispersed in water-insoluble micropowder in the described water-soluble high-molecular material;
In the gross weight of film, the weight content of dextromethorphan hydrobromide is 1～40%, preferably 7～30%;
Described water-soluble high-molecular material is any two kinds among HPMC, PVA, HPC, CMC-Na, PVP, sodium alginate or the PEO, and wherein, a kind of is the lower molecular weight water-soluble high-molecular material, and its molecular weight is 10,000～200,000 dalton, another kind is the higher molecular weight water-soluble high-molecular material, and its molecular weight is 200,000～10,000,000 dalton;
The chemical name of HPMC is hypromellose, the chemical name of PVA is polyvinyl alcohol, and the chemical name of HPC is hydroxypropyl cellulose, and the chemical name of CMC-Na is sodium carboxymethyl cellulose, the chemical name of PVP is polyvinylpyrrolidone, and the chemical name of PEO is polyoxyethylene;
Weight ratio is:
Lower molecular weight water-soluble high-molecular material: higher molecular weight water-soluble high-molecular material=1: 4～4: 1;
Preferably, described water-soluble high-molecular material is that molecular weight is that 130,000 daltonian PVA and molecular weight are the mixture of 600,000 daltonian HPC, and weight ratio is 4: 1;
Perhaps be:
Molecular weight is that 20,000 daltonian HPMC and molecular weight are the mixture of 7,000,000 daltonian PEO, and weight ratio is 1: 4;
Perhaps be:
Molecular weight is that 32,000 daltonian sodium alginates and molecular weight are 700,000 daltonian mixture, and weight ratio is 1: 2;
Perhaps be:
Molecular weight is that 100,000 daltonian PEO and molecular weight are 360,000 daltonian PVP mixture, and weight ratio is 1: 1;
Perhaps be
Molecular weight is that 10,000 daltonian PVP and molecular weight are the mixture of 1,000,000 daltonian HPC, and weight ratio is 2: 1.
Described water-insoluble micropowder is preferably microcrystalline Cellulose micropowder, starch, fine silica powder, CaCO3 micropowder, kayexalate micropowder, CMC micropowder or chitosan micropowder, and the particle diameter of micropowder is 0.1～100 μ m, preferred 1～50 μ m;
The weight ratio of water-soluble high-molecular material and water-insoluble micropowder is:
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.05～1.5;
Preferably:
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.1～1.25;
The aperture of described micropore is 10～100nm, and the thickness of thin film is 0.01～0.2mm;
Further, in the described membrane, also comprise other adjuvants, described other adjuvants are more than one in antioxidant, correctives, plasticizer or the pigment, and in the gross weight of membrane, the weight content of other adjuvants is 0.01～30%;
Described antioxidant is vitamin C, BHA, BHT, vitamin E, EDTA, fumaric acid, maleic acid, tartaric acid, lysine, arginine, sodium sulfite or sodium sulfite etc.;
Described correctives comprises more than one in sweeting agent, acidic flavoring agent, aromatic, gummy macromolecular material, lecithin, cephalin or the phosphatidic acid etc.;
Described sweeting agent such as xylitol, leaf dulcin, Radix Glycyrrhizae ester glycosides, stevioside, saccharin sodium, aspartame, sucralose, acesulfame potassium or cyclamate etc.;
Described acidic flavoring agent such as citric acid, malic acid, ascorbic acid or glycine etc.;
Described aromatic such as Eucalyptus oil, oleum Citri sinensis, Oleum menthae, Oleum menthae, MENTHOL or vanillin etc.;
Described gummy macromolecular material such as xanthan gum, guar gum, tragakanta, cover its glue, locust bean gum or Radix Acaciae senegalis etc.;
Described plasticizer is selected from more than one in Polyethylene Glycol (PEG), glycerol, triacetyl glycerine, triethyl citrate or the Tween 80;
Described pigment is titanium dioxide, shellac color, alkermes, beet red, carthamin, curcumin, beta-carotene, chlorophyll, sunset yellow, lemon yellow, viride nitens or fast green etc.
The preparation method of described dextromethorphan hydrobromide membrane comprises the steps:
(1) pore creating material and active component dextromethorphan hydrobromide are added the water slip of described water-soluble high-molecular material, the weight concentration of the water slip of water-soluble high-molecular material is 10～30%;
The component of described pore creating material comprises described water-insoluble micropowder and absorption solvent thereon, and the parts by weight of water-insoluble micropowder and the weight portion of solvent are:
100 parts of water-insoluble micropowders
100～900 parts of solvents
Described solvent is selected from more than one in ethanol or the acetone, preferred alcohol;
The adding weight of pore creating material, with the weighing scale of butt water-soluble high-molecular material and water-insoluble micropowder, water-soluble high-molecular material: water-insoluble micropowder=1: 0.05～1.5;
Preferably:
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.1～1.25;
(2) then be coated with masking, obtain the medicine carrying thin film;
Described coating masking is the method for this area routine, and such as the method for research (Chinese Journal of Pharmaceuticals, 1977,12 (5)) bibliographical information of nitroderm TTS, the present invention repeats no more;
(3) the medicine carrying thin film that step (2) is obtained is being higher than drying under the temperature of solvent evaporates, obtain described microporous sponge shape medicine film preparation, solvent volatilizees from the water-insoluble micropowder and disengages, and stay next micropore at every water-insoluble micropowder place, and because water-insoluble micropowder capillarity, solvent disengages and is slowly, be conducive to keep uniform bubble formation, because the water-insoluble micropowder is distributed in the macromolecule serosity, thereby just can form comparatively uniformly bubble, what of the particle diameter of water-insoluble micropowder and amount of alcohol have determined again the aperture of micropore, what of the amount of micropore;
Preferably, in step (1), pore creating material, active component dextromethorphan hydrobromide and other adjuvants are added the water slip of described water-soluble high-molecular material, and then be coated with masking, obtain the medicine carrying thin film;
The present invention adopts macromolecular material to consist of network structure, and medicament mixed with joining in the aqueous solution of macromolecular material after the insoluble micropowder absorption of water used in solvent, forms a large amount of micropores by pore creating material again in material.
But the water solublity of dextromethorphan hydrobromide is relatively poor, and bitter in the mouth, needs to add correctives and odor mask, adds the insoluble micropowder in the pore creating material, the large percentage of the water insoluble active ingredient in the prescription.Adopt common way masking, film is crisp, and is frangible, can't normally produce, transports, preserves and use.If strengthen the consumption of plasticizer, the ratio of macromolecule filming material further reduces, and is difficult to film forming.If will in the macromolecule ratio hour guarantee film strength, will use higher molecular weight, material that viscosity is larger, like this, the dissolving of film will be slowed down, and onset is slow.
The inventor finds by a large amount of experiments, if two or more macromolecular material is used, wherein the molecular weight of at least a macromolecular material is 10,000～200,000 dalton, the molecular weight of at least a macromolecular material is 200,000～10,000,000 dalton, the ratio of bi-material is 1: 4～4: 1, just can solve the problems referred to above.The effect of this invention is very significant, and the macromolecular material by lower molecular weight comparatively fast dissolves film, guarantees physical strength and the toughness of film by the macromolecular material of higher molecular weight, has both reached the purpose of rapid release, has guaranteed again film strength.
Description of drawings
Fig. 1 is the Dissolution Rate Testing data.
The specific embodiment
Embodiment 1
Be that 130,000 daltonian PVA and 20g molecular weight are that 600,000 daltonian HPC are dissolved in the 500g water with the 80g molecular weight, be made into the water slip.
100g pore creating material, 10g dextromethorphan hydrobromide, 2g aspartame, 5g glycerol and 3g titanium dioxide are added in the above-mentioned water slip, fully stirring, mix homogeneously.
The component of described pore creating material comprises that particle diameter is chitosan and the absorption acetone thereon of 0.5 μ m, and the parts by weight of chitosan and the weight portion of solvent are:
100 parts of chitosans
400 parts in acetone
(2) then adopt the method for research (Chinese Journal of Pharmaceuticals, 1977,12 (5)) bibliographical information of nitroderm TTS, the coating masking obtains the thin film presoma;
(3) the thin film presoma that step (2) is obtained obtains described thin film for the medicine film preparation in 80 ℃ of dryings, and thickness is 0.07mm.
(4) measure content according to high performance liquid chromatography (two appendix V of Chinese Pharmacopoeia version in 2010 D), cut into every specification that contains hydrobromic acid dextromethorphan 3.75mg, 7.5mg or 15mg.
The weight ratio of each component:
Low-molecular weight water-soluble macromolecular material: high molecular weight water-soluble macromolecular material=4: 1;
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.2;
The aperture of described micropore is 30nm.
Performance evaluation: outward appearance is even, bright and clean.Film strength and toughness are all better.
Embodiment 2
Be that 20,000 daltonian HPMC and 64g molecular weight are that 7,000,000 daltonian PEO is dissolved in the 500g water with the 16g molecular weight, be made into the water slip.
200g pore creating material, 50g dextromethorphan hydrobromide, 5g sucralose and 0.1g sunset yellow are added in the above-mentioned water slip, fully stirring, mix homogeneously.
The component of described pore creating material comprises that particle diameter is kayexalate and the absorption ethanol thereon of 10 μ m, and the parts by weight of kayexalate and the weight portion of solvent are:
100 parts of kayexalates
100 parts of ethanol
Other are with embodiment 1.
The weight ratio of each component:
Low-molecular weight water-soluble macromolecular material: high molecular weight water-soluble macromolecular material=1: 4;
Water-soluble high-molecular material: water-insoluble micropowder=1: 1.25;
The aperture of described micropore is 10nm.
Performance evaluation: outward appearance is even, bright and clean.Film strength and toughness are all better.
Embodiment 3
Be that 32,000 daltonian sodium alginates and 120g molecular weight are that 700,000 daltonian CMC-Na are dissolved in the 700g water with the 60g molecular weight, be made into the water slip.
90g pore creating material, 50g dextromethorphan hydrobromide, 5g cyclamate, 5g PEG400 and 3g titanium dioxide are added in the above-mentioned water slip, fully stirring, mix homogeneously.
The component of described pore creating material comprises that particle diameter is CaCO3 and the absorption ethanol thereon of 1 μ m, and the parts by weight of CaCO3 and the weight portion of solvent are:
100 parts of CaCO3
100 parts of ethanol
Other are with embodiment 1.
The weight ratio of each component:
Low-molecular weight water-soluble macromolecular material: high molecular weight water-soluble macromolecular material=1: 2;
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.25;
The aperture of described micropore is 10nm.
Performance evaluation: outward appearance is even, bright and clean.Film strength is better, and toughness meets the demands.
Be that 100,000 daltonian PEO and 60g molecular weight are that 360,000 daltonian PVP are dissolved in the 600g water with the 60g molecular weight, be made into the water slip.
72g pore creating material, 60g dextromethorphan hydrobromide, 3g acesulfame potassium and 0.1g lemon yellow pigment are added in the above-mentioned water slip, fully stirring, mix homogeneously.
The component of described pore creating material comprises that particle diameter is microcrystalline Cellulose and the absorption ethanol thereon of 20 μ m, and the parts by weight of microcrystalline Cellulose and the weight portion of solvent are:
100 parts of microcrystalline Cellulose
300 parts of ethanol
Other are with embodiment 1.
The weight ratio of each component:
Low-molecular weight water-soluble macromolecular material: high molecular weight water-soluble macromolecular material=1: 1;
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.5;
The aperture of described micropore is 20nm.
Performance evaluation: outward appearance is even, bright and clean.The toughness of film is better, and intensity can meet the demands.
Embodiment 5
Be that 10,000 daltonian PVP and 30g molecular weight are that 1,000,000 daltonian HPC is dissolved in the 400g water with the 60g molecular weight, be made into the water slip.
90g pore creating material, 20g dextromethorphan hydrobromide, 5g aspartame and 5g titanium dioxide are added in the above-mentioned water slip, fully stirring, mix homogeneously.
The component of described pore creating material comprises that particle diameter is fine silica powder and the absorption acetone thereon of 50 μ m, and the parts by weight of fine silica powder and the weight portion of solvent are:
100 parts of fine silica powders
900 parts in acetone
Other are with embodiment 1.
The weight ratio of each component:
Low-molecular weight water-soluble macromolecular material: high molecular weight water-soluble macromolecular material=2: 1;
Water-soluble high-molecular material: water-insoluble micropowder=1: 0.1;
The aperture of described micropore is 50nm.
Performance evaluation: outward appearance is even, bright and clean.Film strength and toughness all can meet the demands.
Get embodiment 1～5 film (specification 7.5mg) each 6, according to dissolution method (two appendix X of Chinese Pharmacopoeia version in 2010 C first method), take 0.1mol/L Klorvess Liquid 500ml as solvent, rotating speed is that per minute 50 turns, in accordance with the law operation through 0.5,1,2,3,5,10, during 15min, is respectively got solution 1ml and is filtered, precision is measured subsequent filtrate 20ul, measures according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2010); Calculate the stripping quantity of different time.Stripping curve is seen Fig. 1.
As seen from Figure 1, the dextromethorphan hydrobromide film according to the prescription of embodiment 1～5 and technique preparation all dissolves in the 3min more than 80%, and the equal dissolve complete of 5min has shown the effect of rapid release.
Embodiment 7
Except not adding the principal agent dextromethorphan hydrobromide, according to prescription and the technique of embodiment 1～5, the preparation blank film is looked for 10 volunteers, membrane is put into mouth begin timing, and per half a minute takes a lick of, and determines that membrane is whether also in mouth.If imperceptible obvious membrane fragment is namely thought stripping of membrane.The dissolution time of record membrane.
Result of the test:
Embodiment 1: dissolution time is 4.7 ± 0.3min, and embodiment 2: dissolution time is 4.6 ± 0.5min, and embodiment 3: dissolution time is 4.2 ± 0.4min, and embodiment 4: dissolution time is 5.0 ± 0.2min, and embodiment 5: dissolution time is 3.9 ± 0.6min.
Get the film (specification 7.5mg) of embodiment 1～5, carry out high temperature, high humidity and exposure experiments to light, investigate the stability of sample.
Hot test: film is put in the culture dish, under 60 ℃ of conditions, placed 10 days, in the 5th day and sampling in the 10th day, detect content, related substance and the dissolution of dextromethorphan hydrobromide in the film.
High wet test: film is put in the culture dish, placed 10 days under relative humidity 75% condition at 25 ℃, in the 5th day and sampling in the 10th day, detect content, related substance and the dissolution of dextromethorphan hydrobromide in the film.
Exposure experiments to light: film is put in the culture dish, is to place 10 days under the condition of 4500Lx ± 500Lx in illumination, in the 5th day and sampling in the 10th day, and content, related substance and the dissolution of dextromethorphan hydrobromide in the detection film.
Testing result sees Table 1～table 5.
Table 1 embodiment 1 stability sample quality inspection result
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 1, the dextromethorphan hydrobromide film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
Table 2 embodiment 2 stability sample quality inspection results
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 2, the dextromethorphan hydrobromide film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
Table 3 embodiment 3 stability sample quality inspection results
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 3, the dextromethorphan hydrobromide film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
Table 4 embodiment 4 stability sample quality inspection results
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 4, the dextromethorphan hydrobromide film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
Table 5 embodiment 5 stability sample quality inspection results
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 5, the dextromethorphan hydrobromide film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
The comparative example 1
Be that 130,000 daltonian PVA are dissolved in the 400g water with the 100g molecular weight, be made into the water slip.All the other are with embodiment 1.
Performance evaluation: outward appearance is even, bright and clean.But film is very crisp, be dried to lick Cheng Zhongyi split, frangible.
Be that 600,000 daltonian HPC are dissolved in the 600g water with the 100g molecular weight, be made into the water slip.All the other are with embodiment 1.
Performance evaluation: outward appearance is even, bright and clean.Film strength and toughness are all better.But the film dissolving is slower, and 30min is stripping medicine 63% only, 60min stripping 89%.Do not meet the requirement of clinical use.
The comparative example 2
Be that 20,000 daltonian HPMC are dissolved in the 300g water with the 80g molecular weight, be made into the water slip.All the other are with embodiment 2.
Performance evaluation: outward appearance is even, bright and clean.But film is very crisp, be dried to lick Cheng Zhongyi split, frangible.
Be that 7,000,000 daltonian PEO is dissolved in the 700g water with the 80g molecular weight, be made into the water slip.All the other are with embodiment 2.
Performance evaluation: film strength and toughness are fine, but the uniformity and fineness are relatively poor.And dissolving slowly, and 30min is stripping medicine 25% only, 60min stripping 42%.Do not meet the requirement of clinical use.
The comparative example 3
Be that 32,000 daltonian sodium alginates are dissolved in the 500g water with the 180g molecular weight, be made into the water slip.All the other are with embodiment 3.
Performance evaluation: film is very crisp, and is frangible, is difficult to complete peeling off.
Be that 700,000 daltonian CMC-Na are dissolved in the 900g water with the 180g molecular weight, be made into the water slip.All the other are with embodiment 3.
Performance evaluation: film strength and toughness are better, but the uniformity and fineness are not good enough.And dissolving slowly, and 30min is stripping medicine 33% only, 60min stripping 52%.Do not meet the requirement of clinical use.
The comparative example 4
Be that 100,000 daltonian PEO are dissolved in the 500g water with the 120g molecular weight, be made into the water slip.All the other are with embodiment 4.
Performance evaluation: outward appearance is even, bright and clean.But film is more crisp, and frangible when cutting packing, outward appearance is imperfect, dosage is inaccurate and cause.
Be that 360,000 daltonian PVP are dissolved in the 700g water with the 120g molecular weight, be made into the water slip.All the other are with embodiment 4.
Performance evaluation: outward appearance is even, bright and clean, and film strength and toughness are better.But dissolve slowlyer, 30min is stripping medicine 68% only, 60min stripping 87%.Do not meet the requirement of clinical use.
The comparative example 5
Be that 10,000 daltonian PVP are dissolved in the 300g water with the 90g molecular weight, be made into the water slip.All the other are with embodiment 5.
Performance evaluation: film is crisp, and is frangible, can't completely peel off.
Be that 1,000,000 daltonian HPC is dissolved in the 500g water with the 90g molecular weight, be made into the water slip.All the other are with embodiment 5.
Performance evaluation: film strength and toughness are better.Outward appearance is bright and clean, but the uniformity is not good enough.And dissolving slowly, and 30min is stripping medicine 29% only, 60min stripping 48%.Do not meet the requirement of clinical use.
Claims (7)
1. have the spongiform dextromethorphan hydrobromide membrane of micropore, it is characterized in that, its component comprises dextromethorphan hydrobromide, water-soluble high-molecular material and is dispersed in water-insoluble micropowder in the described water-soluble high-molecular material;
Described water-soluble high-molecular material is any two kinds among HPMC, PVA, HPC, CMC-Na, PVP, sodium alginate or the PEO, and wherein, a kind of is the lower molecular weight water-soluble high-molecular material, its molecular weight is 10,000～200,000 dalton, another kind is the higher molecular weight water-soluble high-molecular material, its molecular weight is 200,000～10,000,000 dalton, in the gross weight of membrane, the weight content of dextromethorphan hydrobromide is 1～40%;
The weight ratio of described lower molecular weight water-soluble high-molecular material and described higher molecular weight water-soluble high-molecular material is: the lower molecular weight water-soluble high-molecular material: higher molecular weight water-soluble high-molecular material=1: 4～4: 1;
Described water-insoluble micropowder is microcrystalline Cellulose micropowder, starch, fine silica powder, CaCO3 micropowder, kayexalate micropowder, CMC micropowder or chitosan micropowder, and the particle diameter of micropowder is 0.1～100 μ m;
The weight ratio of water-soluble high-molecular material and water-insoluble micropowder is: water-soluble high-molecular material: water-insoluble micropowder=1: 0.05～1.5.
2. the spongiform dextromethorphan hydrobromide membrane with micropore according to claim 1 is characterized in that, in the gross weight of membrane, the weight content of dextromethorphan hydrobromide is 7～30%.
3. the spongiform dextromethorphan hydrobromide membrane with micropore according to claim 1 is characterized in that, described water-soluble high-molecular material is that molecular weight is 130,000 daltonian PVA: molecular weight is 600,000 daltonian HPC=4: 1;
Perhaps be:
Molecular weight is 20,000 daltonian HPMC: molecular weight is 7,000,000 daltonian PEO=1: 4;
Perhaps be:
Molecular weight is 32,000 daltonian sodium alginates: molecular weight is 700,000 daltonian CMC-Na=1: 2;
Perhaps be:
Molecular weight is 100,000 daltonian PEO: molecular weight is 360,000 daltonian PVP=1: 1;
Perhaps be
Molecular weight is 10,000 daltonian PVP: molecular weight is 1,000,000 daltonian HPC=2: 1.
4. the spongiform dextromethorphan hydrobromide membrane with micropore according to claim 1 is characterized in that the weight ratio of water-soluble high-molecular material and water-insoluble micropowder is: water-soluble high-molecular material: water-insoluble micropowder=1: 0.1～1.25.
5. the spongiform dextromethorphan hydrobromide membrane with micropore according to claim 1 is characterized in that the aperture in hole is 10～100nm, and the thickness of thin film is 0.01～0.2mm.
6. the spongiform dextromethorphan hydrobromide membrane with micropore according to claim 1, it is characterized in that, also comprise other adjuvants, described other adjuvants are more than one in antioxidant, tween 80, correctives, plasticizer or the pigment, in the gross weight of membrane, the weight content of other adjuvants is 0.01～30%.
7. each described method with spongiform dextromethorphan hydrobromide membrane of micropore of preparation claim 1～6 is characterized in that, comprises the steps:
(1) pore creating material and active component dextromethorphan hydrobromide are added the water slip of described water-soluble high-molecular material, the weight concentration of the water slip of water-soluble high-molecular material is 10～30%;
The component of described pore creating material comprises described water-insoluble micropowder and absorption solvent thereon, and the parts by weight of water-insoluble micropowder and the weight portion of solvent are:
100 parts of water-insoluble micropowders
100～900 parts of solvents
Described solvent is selected from more than one in ethanol or the acetone;
The adding weight of pore creating material, with the weighing scale of butt water-soluble high-molecular material and water-insoluble micropowder, water-soluble high-molecular material: water-insoluble micropowder=1: 0.05～1.5;
(2) then be coated with masking, obtain the medicine carrying thin film;
(3) the medicine carrying thin film that step (2) is obtained obtains described spongiform dextromethorphan hydrobromide membrane with micropore being higher than drying under the temperature of solvent evaporates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210122530 CN102641258B (en) | 2012-04-24 | 2012-04-24 | Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210122530 CN102641258B (en) | 2012-04-24 | 2012-04-24 | Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102641258A CN102641258A (en) | 2012-08-22 |
| CN102641258B true CN102641258B (en) | 2013-04-24 |
Family
ID=46654508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210122530 Active CN102641258B (en) | 2012-04-24 | 2012-04-24 | Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102641258B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705493B (en) * | 2013-12-24 | 2014-11-12 | 山西皇城相府药业有限公司 | Dextromethorphan hydrobromide oral dispersible film agent and preparation method thereof |
| CN104013606A (en) * | 2014-06-24 | 2014-09-03 | 万特制药(海南)有限公司 | Dextromethorphan hydrobromide film agent and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574329A (en) * | 2009-06-12 | 2009-11-11 | 上海现代药物制剂工程研究中心有限公司 | Zolpidem tartrate film agent |
| CN102028672A (en) * | 2010-09-29 | 2011-04-27 | 上海现代药物制剂工程研究中心有限公司 | Microporous spongy film preparation and preparation method thereof |
-
2012
- 2012-04-24 CN CN 201210122530 patent/CN102641258B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574329A (en) * | 2009-06-12 | 2009-11-11 | 上海现代药物制剂工程研究中心有限公司 | Zolpidem tartrate film agent |
| CN102028672A (en) * | 2010-09-29 | 2011-04-27 | 上海现代药物制剂工程研究中心有限公司 | Microporous spongy film preparation and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 速溶膜剂;黄胜炎;《上海医药》;20051231;第26卷(第7期);305-306 * |
| 黄胜炎.速溶膜剂.《上海医药》.2005,第26卷(第7期),305-306. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102641258A (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657635B (en) | Spongy asenapine sublingual film agent with micropores and preparation method thereof | |
| CN103099799B (en) | Composite film-like preparation and preparation method thereof | |
| CN103083284B (en) | Film preparation and its preparation method | |
| CN103083283B (en) | Loratadine film preparation | |
| CN104546807B (en) | Olanzapine oral instant film agent | |
| CN103784426B (en) | Molten membrane of Aripiprazole mouth and preparation method thereof | |
| CA2966714A1 (en) | Dexamethasone oral film | |
| CN102028672B (en) | Microporous spongy film preparation and preparation method thereof | |
| CN101574330A (en) | Rizatriptan benzoate film agent | |
| CN102846581A (en) | Ambroxol hydrochloride oral fast-dissolving film and preparation method thereof | |
| CN102309562B (en) | Preparation method of taste-masked suspension granules of Gegenqinlian decoction | |
| CN102641258B (en) | Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof | |
| CN103393624B (en) | Montelukast sodium membrane-shape preparation | |
| Garsuch | Preparation and characterization of fast-dissolving oral films for pediatric use | |
| CN1775289B (en) | Multi vitamin oral disintegrating tablet formulation and its preparing method | |
| CN102670570B (en) | Microporous spongy ondansetron hydrochloride film agent and preparation method thereof | |
| CN101574329A (en) | Zolpidem tartrate film agent | |
| CN101849926B (en) | Zolpidem tartrate film | |
| CN103349657B (en) | Risperidone film-shaped preparation | |
| CN101732286B (en) | Voglibose film and preparation method thereof | |
| Saeed et al. | Effect of natural/synthetic polymers and super disintegrants on the formulation of zafirlukast fast dissolving film | |
| KR101546667B1 (en) | Fast dissolving oral dosage form of Sildenafil improved the property of matter and shielding a bitter taste | |
| CN103356512B (en) | Benzenesulfonic acid amlodipine membranaceous preparation | |
| Gholve et al. | Orodispersible tablets: a systematic review | |
| CN103142608B (en) | Codeine phosphate and promethazine hydrochloride compound membranous preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201203, 1111 Harley Road, Shanghai, Pudong New Area Patentee after: SHANGHAI MODERN PHARMACEUTICAL ENGINEERING INVESTIGATION CENTER Co.,Ltd. Patentee after: Kangzhi Pharmaceutical Co., Ltd Address before: 201203, 1111 Harley Road, Shanghai, Pudong New Area Patentee before: SHANGHAI MODERN PHARMACEUTICAL ENGINEERING INVESTIGATION CENTER Co.,Ltd. Patentee before: Hainan Kangzhi Pharmaceutical Co., Ltd |
|
| CP01 | Change in the name or title of a patent holder |